EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

Corynn Kasap iD, Adila Izgutdina iD, Bonell Patiño-Escobar iD, Amrik S Kang iD, Nikhil Chilakapati iD, Naomi Akagi, Ananya Manoj iD, Haley Johnson iD, Tasfia Rashid, Juwita Werner iD, Abhilash Barpanda iD, Huimin Geng und 33 weitere

Blood · 14.08.2025 · 146 (7) · 819-833

DOI: 10.1182/blood.2024025536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 14.08.2025. Verfasst von Corynn Kasap und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, CD27 Ligand. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the success of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T cells (CAR-Ts) in multiple myeloma, patients with high-risk cytogenetic features continue to relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested single-chain variable fragment–based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape–mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveCD27 LigandReceptors, Chimeric AntigenUp-RegulationGene Expression Regulation, NeoplasticEpigenomicsMachine LearningTranscription FactorsGene Regulatory NetworksHumansMolecular Targeted TherapyTumor EscapeB-Cell Maturation Antigen

Substanzen

Receptors, Chimeric AntigenCD70 protein, humanCD27 LigandTranscription FactorsB-Cell Maturation Antigen

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA.
  • Medical Scientist Training Program, University of California San Francisco, San Francisco, CA.
  • Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA.
  • Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA.

ORCID-Profile: Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, Amrik S Kang, Nikhil Chilakapati, Ananya Manoj, Haley Johnson, Juwita Werner, Abhilash Barpanda, Sham Rampersaud, Daniel Gil-Alós, Adolfo Aleman, Gianina Wicaksono, Radhika Dalal, Juan Antonio Camara Serrano, Alfred Chung, Lawrence H Boise, Elliot Stieglitz, Jonathan D Licht, Benjamin G Barwick, Arun P Wiita

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Kasap, C., Izgutdina, A., Patiño-Escobar, B., Kang, A. S., Chilakapati, N., Akagi, N., Manoj, A., Johnson, H., Rashid, T., Werner, J., Barpanda, A., Geng, H., Lin, Y. T., Rampersaud, S., Gil-Alós, D., Sobh, A., Dupéré-Richer, D., Aleman, A., Wicaksono, G., …, & Wiita, A. P. (2025). Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells. Blood, 146(7), 819-833. https://doi.org/10.1182/blood.2024025536

Vancouver

Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, et al. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells. Blood. 2025;146(7):819-833. doi:10.1182/blood.2024025536

BibTeX
@article{Kasap2025,
  author = {Kasap, Corynn and Izgutdina, Adila and Patiño-Escobar, Bonell and Kang, Amrik S and Chilakapati, Nikhil and Akagi, Naomi and Manoj, Ananya and Johnson, Haley and Rashid, Tasfia and Werner, Juwita and Barpanda, Abhilash and Geng, Huimin and Lin, Yu-Hsiu T and Rampersaud, Sham and Gil-Alós, Daniel and Sobh, Amin and Dupéré-Richer, Daphné and Aleman, Adolfo and Wicaksono, Gianina and Kelii, K M Kawehi and Dalal, Radhika and Ramos, Emilio and Vijayanarayanan, Anjanaa and Lakhani, Kiran and Salangsang, Fernando and Phojanakong, Paul and Camara Serrano, Juan Antonio and Zakraoui, Ons and Tariq, Isa and Chari, Ajai and Chung, Alfred and Kumar, Anupama D and Martin, Thomas G and Wolf, Jeffrey and Wong, Sandy W and Steri, Veronica and Shanmugam, Mala and Boise, Lawrence H and Kortemme, Tanja and Parekh, Samir and Stieglitz, Elliot and Licht, Jonathan D and Karlon, William J and Barwick, Benjamin G and Wiita, Arun P},
  title = {Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells},
  journal = {Blood},
  year = {2025},
  volume = {146},
  number = {7},
  pages = {819--833},
  doi = {10.1182/blood.2024025536}
}
Kostenlos starten →